Search

Search Constraints

You searched for: Author/Creator Kosco‐Vilbois, Marie

Search Results

1. ACI‐24 in adults with Down syndrome: Results of a phase 1b, randomized, placebo‐controlled study. (31st December 2021)

2. ACI‐24 in adults with Down syndrome: Results of a phase 1b, randomized, placebo‐controlled study. (31st December 2021)

3. ACI‐24 vaccine in adults with Down syndrome: Human: Putative therapeutic results for Alzheimer's and related dementias. (7th December 2020)

4. Biomarker‐based development for optimized ACI‐24, a novel candidate vaccine for the treatment and prevention of Alzheimer's disease. (20th December 2022)

5. Developing a novel alpha‐synuclein positron emission tomography (PET) tracer for the diagnosis of synucleinopathies: Neuroimaging: Other neurodegenerative disorders. (7th December 2020)

6. Discovery of [18F]ACI‐12589, a Novel and Promising PET‐Tracer for Alpha‐Synuclein. (20th December 2022)

7. IL‐17F co‐ ;expression improves cell growth characteristics and enhances recombinant protein production during CHO cell line engineering1. Issue 4 (23rd November 2012)

8. Initial clinical scans using [18F]ACI‐12589, a novel α‐synuclein PET‐tracer. (20th December 2022)

9. Optimized ACI‐24, an amyloid beta (Abeta) vaccine that safely drives immunity to oligomers and Pyroglutamate Abeta, key pathological species of Alzheimer's disease (AD). (20th December 2022)

10. Spatiotemporal expression of endogenous TLR4 ligands leads to inflammation and bone erosion in mouse collagen‐induced arthritis. Issue 11 (6th September 2016)